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Aurora kinases have become a hot topic for research as they have been found to play an important role in various stages of mi-
totic cell division and to participate in malignant conversions of tumors. The participation of Aurora kinases in the regulation 
of oocyte meiosis has been recently reported, but their participation in mammalian early embryonic development remained un-
clear. The object of our study was to establish the spatio-temporal expression pattern of Aurora kinase B (AURKB) in mouse 
zygotes during the first cleavage, to reveal its functions in the early development of mouse zygotes, and to define the involve-
ment of AURKB in mitogen-activated protein kinase (MAPK) signaling. Our results showed that in mouse zygotes AURKB 
expression increased in G1 phase and peaked in M phase. AURKB protein distribution was found to be in association with nu-
clei and distributed throughout the cytoplasm in a cell cycle-dependent manner. Functional disruption of AURKB resulted in 
abnormal division phenotypes or mitotic impairments. U0126, a specific mitogen-activated protein kinase kinase (MEK) inhib-
itor, caused significantly altered morphologies of early embryos together with a decrease in protein expression and kinase ac-
tivity of AURKB. Our results indicated that the activity of AURKB was required for regulating multiple stages of mitotic pro-
gression in the early development of mouse zygotes and was correlated with the activation of the MAPK pathway. 
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Aurora kinases have been implicated in several vital events 
in mitosis. They represent a serine/threonine kinase family 
highly conserved during evolution. Aurora kinases are dif-
ferent in their sub-cellular distribution and functions. In 
somatic cells, Aurora kinase B (AURKB), the “chromoso-
mal passengers” protein, has been found at the midbody of 
anaphase cells and at the post-mitotic bridge of telophase 
cells, participating in chromatin modification, microtu-
bule-kinetochore attachment, spindle checkpoint and cyto-
kinesis [1]. Aurora kinases are over-expressed in a variety 
of tumor cell lines, suggesting that these kinases might play 
a role in tumorigenesis, and have already become potential 
targets for cancer diagnosis and therapy. Aurora kinases in 
reproductive germ cells have been the focus of interest for 
researchers in recent years, and little was known on the 
subject till now. Studies have shown that meiotically in-
competent mouse oocytes contained transcripts for all three 
AURK isoforms and transcript levels remained unchanged 
as oocytes progressed through meiosis, with AURKA being 
the predominant isoform. Inhibition of Aurora kinases re-
sulted in aberrant chromatin remodeling and significantly 
fewer cells progressing to meiosis II (MII). AURKA 
over-expression triggered abnormal amplification of cen-
trosomes, while AURKB-over-expressed oocytes failed in 
48 Xu L, et al.   Sci China Life Sci   January (2012) Vol.55 No.1 
proper chromosomal arrangement [2,3]. These studies 
prompted us to question how Aurora kinases would function 
during development after fertilization. In somatic cells, Au-
rora kinases have been identified as important regulators of 
mitotic divisions. Nevertheless, little was known about the 
involvement of Aurora kinases in mammalian embryonic 
development. 
Mitogen-activated protein kinase (MAPK) cascades are 
highly conserved and have central roles in diverse cellular 
functions. Studies on progesterone-induced maturation of 
Xenopus oocytes indicated that over-expression of kinase 
Eg2, a Xenopus member of the Aurora/Ipl1 family, activat-
ed the MAP kinase pathway [4]. This study raises the possi-
bility that Aurora kinase signals through the MAPK signal-
ing pathway. There have been some reports indicating 
crosstalk between AURKA and MAPK [5,6]. As for the 
relationship between AURKB and MAPK, Kanda et al. [7] 
showed that AURKB kinase activity was involved in 
Ras-mediated cell transformation. Eves et al. [8] demon-
strated that the loss of Raf kinase inhibitory protein (RKIP) 
through hyperactivation of the Raf/MEK/ERK1,2 signaling 
cascade regulated the mitotic checkpoint via inhibition of 
AURKB. However, Kosik et al. [9] argued against the di-
rect role for Aurora kinases in the Ras/MAPK pathway: 
they found that AURKA activity was not a major require-
ment for Ras/MAPK signaling. Another report demonstrat-
ed that during oocyte maturation, active matura-
tion-promoting factor (MPF) was necessary and sufficient 
to induce AURKA phosphorylation and activation, inde-
pendently of the Mos/MAPK pathway [10]. In mammals, 
MAPK members include extracellular signal-regulated ki-
nases 1 and 2 (ERK1/2; MAPK3 and MAPK1, respectively). 
There have been some observations clearly demonstrating 
that Mos, MAPK and MAPK substrates are all involved in 
regulating microtubule dynamics and the size of the first 
polar body of mouse oocytes [11,12]. However, there is 
limited information related to understanding of Aurora ki-
nases and MAPK interaction in regulating early embryonic 
development in mice, which is important to further under-
stand the mechanism of these kinases regulating cell cycle 
events. A previous study identified the expression of 
AURKA in mouse zygotes [13]. The objectives of our study 
were to determine the expression pattern of AURKB during 
the first cleavage in mouse zygotes, to examine the effects 
of functional disruption of AURKB during early develop-
ment of mouse zygotes, and to identify the involvement of 
AURKB in the MAPK pathway. 
1  Materials and methods 
1.1  Chemicals 
All the chemicals used in this study were purchased from 
Sigma Aldrich Corporation (USA) except for those specifi-
cally mentioned. MEK inhibitor U0126 was prepared as a 
stock solution dissolved in dimethyl sulfoxide (DMSO). 
Hyaluronidase was prepared in M2 medium directly and 
stored at 20°C. 
1.2  Mouse stimulation, fertilization and collection of 
zygotes 
Kunming white strain mice were used in this study. Animal 
care and handling were conducted in accordance with poli-
cies on the care and use of animals promulgated by the eth-
ical committee of China Medical University. Female mice 
were injected with 10 IU of pregnant mare serum gonado-
tropin (PMSG) and then with 10 IU of human chorionic 
gonadotropin (hCG) 48 h later. In vivo-fertilized zygotes 
were collected 19 h post hCG injection from the oviduct 
ampullae of super-ovulated females that had mated with 
males of the same strain. After removing cumulus cells with 
300 IU mL1 hyaluronidase in M2 medium, zygotes were 
cultured and kept in M16 medium at 37°C in a humidified 
atmosphere of 5% CO2 until use. The development model of 
mouse one-cell embryos is as follows: G1 phase, 12–21 h 
post hCG injection; S phase, 21–27 h post hCG injection; 
G2 phase, 27–30 h post hCG injection; M phase, 30–33 h 
post hCG injection. 
1.3  RNA isolation, reverse transcription and real time 
PCR 
Zygote total mRNA was extracted from 100 zygotes at each 
development stage using the Illustra QuickPrep Micro 
mRNA Purification Kit (GE Healthcare, Boston, MA, USA) 
according to the manufacturer’s instructions. Zygote cDNA 
was synthesized using 20 pmol dT primer, 0.5 mmol L1 
dNTP, 20 U RNase inhibitor and 1 μL ImProm-II Reverse 
Transcriptase (Promega, Madison, WI, USA) in a final 
volume of 20 µL. For each gene, species-specific primers 
crossing exon junction were designed using the sequences 
acquired from the GenBank database. The primers for 
mouse AURKB (GenBank ID: NM_011496.1) were forward 
primer 5′-GCCAAAGTCTGCAATCTTCA-3′; reverse pri-
mer 5′-CCTGACCTACTGCCACAAGA-3′. The following 
primers were used for ACTB (GenBank ID: NM_007393.3): 
forward primer 5′-GTCTTTACGGATGTCAACG-3′; re-
verse primer 5′-TTTCCAGCCTTCCTTCTT-3′. Real time 
PCR was performed on the Applied Biosystems 7500 real 
time PCR system (USA). Each PCR was performed with 
2.5 zygote equivalents of cDNA added to QuantiTect SYBR 
Green Master Mix (Qiagen, Boston, MA, USA). Real time 
PCR reactions were carried out for 45 cycles (94°C for 15 s, 
53°C for 30 s, 72°C for 35 s) after an initial 15 min incuba-
tion at 95°C. Data were collected from experiments in three 
replicates with triplicate samples for each gene, and fold 
increases were based on the metaphase of meiosis II-   
arrested egg levels, which were normalized to 1. Data were 
analyzed using comparative Ct (threshold cycle) method. 
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1.4  Western blot analysis 
Groups of zygotes (n=250) were prepared for Western blot 
analysis. Zygotes were placed in 2× sodium dodecyl sul-
phate (SDS)-polyacrylamide gel electrophoresis (PAGE) 
sample loading buffer, vortexed and placed on ice for 15 
min. Following sonication on ice for 10 s, samples were 
denatured at 90°C for 10 min and loaded for electrophoresis. 
Total protein from equal numbers of mouse zygotes was 
loaded in each lane and separated by one-dimensional 
SDS-PAGE. Resolving gels were cast using 12% acryla-
mide, stacking gels contained 5% acrylamide. Gels were 
equilibrated and transferred to PVDF transfer membrane 
(PALL, USA). Blots were blocked in 5% nonfat milk in 
Tris-buffered saline (TBS) with 0.5% Tween (TBST) at 
37°C for 1 h and incubated with the appropriate primary 
antibody diluted in TBST with 5% nonfat milk overnight at 
4°C with agitation. Antibodies included anti-AURKB 
(1:200, Santa Cruz, CA, USA), anti-tERK1/2 (1:1000, Cell 
Signaling, Beverly, MA, USA), anti-pERK1/2 antibody 
(1:1000, Cell Signaling, Beverly, MA, USA) and an-
ti-α-tubulin antibody (1:1000, Beyotime Biotechnology, 
Nantong, China). After washing with TBST, blots were 
incubated with the appropriate horseradish peroxidase 
(HRP)-conjugated IgG secondary antibody (1:4000, Santa 
Cruz, CA, USA) at room temperature for 1 h, washed in 
TBST and developed with ECL Plus reagents (Beyotime 
Biotechnology, Nantong, China) according to the manufac-
turer’s instructions. Band densities were assessed using NIH 
imaging software, Image J. 
1.5  Plasmid construction and microinjection 
We used the mammalian expression vector pGPU6/GFP/ 
Neo (GenePharma, Shanghai, China) to direct the synthesis 
of small interfering RNA (siRNA)-like transcript for sup-
pression of AURKB expression. Two 64-mer oligos for 
AURKB short hairpin RNA (shRNA), one forward 
5′-CACCGCCAGAAGTTGGTCGAGAACATTCAAGAG
ATGTTCTCAGCCAACTTCTGGCTTTTTTG-3′, one re-
verse 5′-GATCCAAAAAACCAGAATTTGGCTGAGAA-  
CATCTCTTGAATGTTCTCAGCCAACTTCTGGC-3′,  
were synthesized (GenePharma, Shanghai, China), annealed, 
phosphorylated and ligated into the Bbs I and BamH I re-
striction sites of the digested pGPU6/GFP/Neo vector. The 
recombinant plasmid was sequenced to verify the correct 
insert. The plasmid was diluted in endotoxin-free TE buffer 
(pH 7.4) at different concentrations and microinjected into 
zygotes in G1 phase using the TransferMan microinjection 
system (Eppendorf, Germany) and a model IX-70 inverted 
microscope (Olympus, Japan) with Hoffmann optics. Typi-
cal injection volume was 5% of the total cell volume or 10 
pL per zygote. Green fluorescent protein (GFP) expression 
was examined 24 h after microinjection using a fluores-
cence microscope (Olympus, Japan). Zygotes expressing 
GFP were collected for further experiments. Zygotes in-
jected with TE buffer or scrambled shRNA served as nega-
tive controls. 
1.6  Zygote culture and MEK inhibition 
MEK inhibitor U0126 was dissolved in DMSO to obtain a 
10 mmol L1 stock. Stock solution was dissolved in M2 
medium to obtain final concentrations of 10, 20, 30 µmol 
L1. Control treatments contained 0.1% DMSO. To assess 
the effects of MEK inhibition on zygotic development, zy-
gotes in G1 phase were cultured in the presence or absence 
of various doses of U0126. Zygotes were assessed by West-
ern blot analysis to determine the optimal inhibition con-
centration at 33 h post hCG injection. To determine the ef-
fects of ERK1/2 inactivation, G1 zygotes were incubated in 
vitro until M phase in the presence or absence of U0126 and 
then subjected to immunofluorescence staining and confocal 
microscopy or processed for morphology detection by phase 
contrast microscopy (Nikon, Japan). 
1.7  Immunofluorescence 
To investigate the spatial pattern of AURKB, zygotes were 
fixed in 4% paraformaldehyde in phosphate buffered saline 
(PBS) (pH 7.4) for at least 30 min at room temperature. 
After being permeabilized with 3% Triton X-100 at 37°C 
for 15 min, zygotes were blocked in 2% bovine serum al-
bumin (BSA) at 37°C for 30 min and incubated at 4°C 
overnight with goat anti-AURKB (1:100, Santa Cruz, CA, 
USA). After three washes with the blocking solution, the 
appropriate Alexa 594 conjugated secondary antibodies 
(Millipore, Bedford, MA, USA) were added at a 1:500 dilu-
tion for 1 h at 37°C. Following washing, slides were incu-
bated with 4 mg mL1 Hoechst 33342 in PBS for 5 min at 
37°C. For double-staining of AURKB and α-tubulin, goat 
anti-AURKB antibody and mouse anti-α-tubulin antibody 
(1:500, Beyotime Biotechnology, Nantong, China) were 
added together and the secondary antibodies used were 
Alexa 594 and FITC-conjugated, respectively. For dou-
ble-staining of pERK1/2 and AURKB, the above method 
was employed, except that one of the primary antibodies 
used was 1:500 rabbit anti-pERK1/2 antibody. Coverslips 
were then mounted on glass slides with 90% glycerol in 
PBS for fluorescence microscopic visualization under a 
laser scanning confocal microscope at ×400 magnification 
(Olympus, Japan). 
1.8  AURKB activity assay 
Zygotes were collected, 15 per group, and lysed at 4°C in 4 
volumes of EB buffer (80 mmol L1 β-glycerophosphate, 
pH 7.3, 20 mmol L1 EGTA, 15 mmol L1 MgCl2, 1 mmol 
L1 dithiothreitol), supplemented with protease inhibitor 
mixture and 1 µmol L1 okadaic acid. Lysates were centri- 
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fuged at 15000×g at 4°C for 15 min and then immunopre-
cipitated with anti-AURKB antibody. Histone H3 kinase 
activity of AURKB was assayed in the corresponding im-
munoprecipitates, incubated for 30 min at 30°C in the pres-
ence of kinase buffer (50 mmol L1 Tris-HCl, pH 7.2, 15 
mmol L1 MgCl2, 5 mmol L1 EGTA, 1 mmol L1 dithio-
threitol) containing 3 µCi of [γ-32P] ATP (Beijing FuRui 
Biotechnology, Beijing, China), 50 µmol L1 ATP and 0.5 
mg mL1 of histone H3. Kinase reaction was stopped by 
adding Laemmli buffer and boiling. After electrophoresis 
and autoradiography, the band corresponding to histone H3 
was excised, and the associated radioactivity was measured 
in a liquid scintillation counter (Beckman Coulter, USA). 
1.9  Statistical analysis 
All experiments were performed independently at least 
three times. Student t-test was used to evaluate the differ-
ences between multiple experimental groups using SPSS 
12.0 software, and the differences were considered statisti-
cally significant at P<0.01. 
2  Results 
2.1  The expression of AURKB in mouse zygotes 
To determine the AURKB isoform present in mouse oocytes, 
an isoform-specific primer was designed for AURKB and 
used in real time PCR for transcript amplification. The re-
sults revealed that AURKB was increasingly expressed from 
phase G1 and peaked at phase M (Figure 1A). Accordingly, 
the Western blot analysis indicated a similar protein expres-
sion pattern. Polyclonal goat antibody to AURKB revealed 
a single protein at approximately 39 kD in an extract pre-
pared from 250 zygotes (Figure 1B). Thus, AURKB was 
expressed at four phases during the first cleavage in mouse 
zygotes, with the amount reaching maximum after the 
commencement of the mitotic process, both at the mRNA 
and protein levels. 
2.2  Localization of AURKB at different stages during 
the first cleavage 
AURKB localization in zygotes during the first cleavage 
was detected using indirect immunofluorescence (Figure 2). 
In G1 and S phase zygotes, it was mainly present in the 
subcortical region and slightly in the cytoplasm. In G2 zy-
gotes, pronuclei broke down and visible nucleoli disap-
peared. The embryo surface was ruffling and the cytoskele-
ton was reorganized preparatory to cleavage. In this phase, 
AURKB was not only dispersed throughout the cytoplasm, 
but also showed accumulation near chromatin. With the 
entrance into anaphase of mitosis, AURKB was expressed 
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Figure 1  The expression pattern of AURKB at four phases during the 
first division of mouse zygotes. A, Graphical representation demonstrating 
fold-increases of AURKB mRNA levels between various zygote types 
obtained from real time PCR. Oocytes arrested in metaphase of meiosis II 
(Met II) were used as the control and were normalized to 1 (not shown). B, 
Detection of mouse AURKB protein by western blotting. α-tubulin was  
used as a loading control. 
 
Figure 2  Localization of AURKB during the process of the first cleavage.  
Red, AURKB; blue, chromatin; merged, overlapping of red and blue. 
2.3  AURKB-knockdown zygotes failed in proper 
chromosome segregation and cytokinesis 
We used RNAi to assess loss-of-function of AURKB during 
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the first mitotic process. Correct recombination of the 
shRNA expression plasmid for AURKB was confirmed by 
sequencing. The plasmid was then injected into the male 
pronuclei of G1 zygotes at concentrations of 0.2, 0.4, 0.6, 
0.8, 1.0 and 1.2 mg mL1, and the zygotes were then cul-
tured in M16 medium for 24 h to allow time for 
RNAi-mediated targeting of mRNA, which was assessed by 
real time PCR and Western blotting. The experiments 
showed that 1.0 mg mL1 was a suitable concentration that 
resulted in the strongest suppression without embryo lethal-
ity caused by over-microinjection. As expected, the level of 
AURKB mRNA decreased significantly (P<0.01) (Figure 
3A). Moreover, a significant difference (P<0.01) in protein 
expression was observed between RNAi groups and control 
groups when analyzed by Western blotting (Figure 3B). We 
then examined the cleavage results after functional disrup-
tion of AURKB. Compared to the two controls, zygotes of 
the AURKB-knockdown group were 50% more likely to 
have abnormal cleavage and asymmetrical cytokinesis 
(Figure 3C and D). 
To further characterize AURKB-RNAi effect, embryos 
were fixed and stained with Hoechst 33342 and antibodies 
specific for AURKB and α-tubulin. Immunofluorescence 
staining revealed that a significantly larger percentage of 
embryos developed to three or more unequal-sized daughter 
cells. AURKB protein staining was nearly absent in each 
embryo (Figure 3E). These results suggest that although 
many zygotes were able to enter cleavage, they were un-
dergoing irregular divisions. 
2.4  The effect of ERK1/2 activity inhibition on the 
cleavage condition in mouse zygotes 
We ascertained the presence of ERK1/2 by Western blot 
analysis at four phases during the first division of mouse 
zygotes. ERK1/2 protein levels increased from G1 phase 
and peaked at M phase. Phospho-ERK1/2 antibody was 
added to confirm that ERK1/2 achieved its highest activity 
during M phase (Figure 4). 
Next, we used U0126, a specific inhibitor of MEK, to 
test whether down-regulation of the MAPK pathway af-
fected the cleavage condition of mouse zygotes. U0126 at 
concentrations of 10, 20 and 30 μmol L1 was used to de-
termine the appropriate working concentration. As shown in 
Figure 5A, 30 μmol L1 U0126 was able to suppress the 
phosphorylation level of ERK1/2 significantly to below 
10% of that of control. We then proceeded with our exper-
iments using that concentration. As shown in Figure 5B, 
altered morphologies were observed after the treatment. 
Nearly 80% of U0126-treated embryos showed abnormal or 
incomplete cytokinesis, and formed two or three daughter 
cells of different sizes or with altered shapes (Figure 5C). 
Almost all zygotes divided, although with clearly altered 
morphologies, and ultimately died before reaching the mor-
ula stage (not shown). 
2.5  AURKB was down-regulated by ERK inactivation 
To determine the effect of ERK inactivation on AURKB, 
zygotes treated with 30 μmol L1 U0126 were collected for 
Western blotting and kinase activity assay. Since U0126 
was used in a final concentration of 0.1% DMSO, we set 
another control group containing 0.1% DMSO. We found 
that AURKB protein was down-regulated both in expres-
sion levels and kinase activity. As shown in Figure 6A, 
AURKB protein was reduced by 68.77% compared to the 
DMSO-treated control, with no significant differences be-
tween the two controls. Next, we analyzed whether the 
MEK inhibitor affected AURKB activity. We observed that 
the activity decreased by 65.86% in response to ERK1/2 
phosphorylation abortion (Figure 6B). These results 
prompted us to investigate whether U0126 altered the 
co-localization of AURKB and phospho-ERK1/2. Control 
embryos were highly fluorescent throughout the cytoplasm 
when double-stained with phospho-ERK1/2 and AURKB 
antibodies, which suggested they shared a similar localiza-
tion pattern. We observed that in the treated group some 
zygotes normally formed a contractile ring between two sets 
of chromosomes but failed to divide normally into two 
identical daughter cells of the same size (Figure 6C(b)). 
Several furrows were also observed in a number of treated 
eggs that formed three sets of chromosomes. Those zygotes 
with multiple furrows seemed to form tripolar embryos 
(Figure 6C(c)). Meanwhile, after the 30 μmol L1 U0126 
treatment, activated ERK1/2 protein became much less de-
tectable, especially in and around newly formed nuclei 
(Figure 6C(b2) and (c2)). The anti-AURKB signal was also 
highly reduced, similar to the change of phospho-ERK1/2 
(Figure 6C(b3) and (c3)), and some fluorescence was visible 
at the membrane (Figure 6C(c3)). 
3  Discussion 
In this study, we determined the expression pattern of 
AURKB during the first cleavage of early mouse embryos. 
The expression level was low in G1/S but high in G2/M and 
peaked at M. This showed a cell cycle-dependent change in 
the expression, similar to that in somatic cells. Mouse or 
bovine oocytes also contain a transcript for AURKB and the 
transcript level increases significantly as oocytes gain mei-
otic competence, but does not change as oocytes progress 
through meiosis to MII [14,15]. We could speculate that 
AURKB might contribute to mouse zygotic development at 
different steps throughout the process of the first mitosis at 
different expression levels. We also analyzed the intracellu-
lar localization of AURKB at four phases throughout the 
first cleavage of mouse zygotes. With lower protein levels 
at G1/S, it was present throughout the cytoplasm and hardly 
detectable around male and female pronuclei. At G2 phase, 
the fluorescence intensity of AURKB increased in the  
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Figure 3  The effect of the microinjection of hairpin siRNA expression plasmid for AURKB. A, AURKB mRNA level in relative arbitrary units after 
RNAi-mediated knockdown. B, Western blot analysis to verify the suppression effect. C, Observation of typical abnormal cleavage of zygotes injected with 
shRNA expression plasmid for AURKB and detection of GFP expression by a fluorescence microscope. D, A bar graph representation of the average ratios 
of normal mitotic cells, arrested/dead cells and those with abnormal cleavage. Zygotes microinjected with the equal volume of endotoxin-free TE buffer and 
equal amount of scrambled shRNA served as control 1 and control 2, respectively. Letters a and b indicate significant differences compared to control 1 and 
control 2, respectively (P<0.01). E, Fluorescence microscopy images of the effects of AURKB deficiency. Red, AURKB; green, α-tubulin; blue, DNA;  
merged, overlapping of red, green and blue. 



































Figure 4  ERK1/2 protein expression at four phases of the first division in 
mouse zygotes. Graphical representation demonstrates relative protein 
expression levels during various zygote phases. 
whole cell and appeared more concentrated and associated 
with the chromosomes. After the zygotes entered mitosis, 
most of AURKB diffused throughout the cytoplasm. The 
success of mitosis depends to a large degree on the interac-
tion between chromosomes and spindle microtubules, and 
the chromosomal passenger complex can coordinate their 
functions. As a member of the chromosomal passenger 
complex, AURKB has its characteristic localization and 
functions. During G2 phase, the protein clearly accumulated 
around the chromosome where it was regulated by other 
members of the passenger protein complex and participated 
in chromosome condensation. Phosphorylation of histone 
H3 at serine-10 during late G2/prophase by AURKB has 
been linked to chromosome condensation, because mutation 
of this phosphorylation site caused chromosomal condensa-
tion and subsequent segregation defects [16,17]. As the  
zygotes progressed through mitosis from metaphase to ana-
phase, the expression of AURKB reached its highest level,  
 
Figure 5  Effects of ERK1/2 inactivation on the cleavage condition of mouse zygotes. A, Western blotting was performed to determine the working con-
centration of U0126. B, Zygotes in G1 phase were treated with 30 μmol L1 U0126 and observed by phase contrast microscopy 33 h post hCG injection. C, 
U0126-treated zygotes showing altered shapes were marked with a star. The bar graph represents the average ratios of normal mitotic cells and those with 
abnormal division. Letters a and b indicate significant differences compared to the non-treated control and 0.1% DMSO-treated control, respectively  
(P<0.01). 
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Figure 6  Effects of ERK1/2 inactivation on AURKB. A, Changes in protein expression of AURKB were detected by Western blotting after U0126 treat-
ment. B, Protein lysates from U0126-treated embryos were immunoprecipitated with anti-AURKB antibody and assayed for AURKB kinase activity by 
scintillation counting and autoradiography using histone H3 as the substrate. The activity was expressed as cpm incorporated in the substrate. Letters a and b 
indicate significant differences compared to the no treatment group and the 0.1% DMSO group, respectively (P<0.01). C, The co-localization of activated 
ERK1/2 and AURKB with or without U0126 treatment. Examples of alterations in U0126-treated embryos observed by confocal imaging are shown in b1b4  
and c1c4. Red, AURKB; green, p-ERK1/2; blue, DNA; merged, overlapping of red, green and blue. 
indicating its significance in cytokinesis. In mouse zygotes, 
from anaphase onwards, AURKB was distributed through-
out the whole cell. Previous studies suggested that depletion 
of AURKB resulted in polyploidy due to a failure in cyto-
kinesis through the phosphorylation of several other pro-
teins involved in cytokinesis, although the mechanism has 
not yet been elucidated [18]. 
Since fewer studies have focused on AURKB in the reg-
ulation of oocyte or embryonic development, in this report 
RNA interference was used to assess the functional effect of 
AURKB disruption in mouse zygotes. According to a pre-
vious report, AURKB was responsible for regulating chro-
mosome dynamics during meiosis in mouse oocytes. 
AURKB inhibition resulted in defects in meiotic progres-
sion and chromosome alignment at both metaphase of mei-
osis I (Met I) and metaphase of meiosis II (Met II), while 
over-expression of AURKB reversed the chromosome 
alignment defect, suggesting that AURKB is the primary 
Aurora kinase responsible for regulating chromosome dy-
namics during meiosis in mouse oocytes [3]. Our results 
indicate that AURKB was required for the development of 
mouse zygotes. In our experiments, disruption of AURKB 
resulted in zygote lethality without completion of cytokine-
sis; in addition, we found that most of the AURKB-deficient 
mouse zygotes failed to divide normally into two identical 
daughter cells. Cytokinesis in some of them was random, 
resulting in multiple daughter cells of different sizes. Dur-
ing cytokinesis it is important that the cleavage furrow is 
positioned correctly between the two daughter nuclei after 
chromosome segregation. Several studies have revealed that 
AURKB controlled the cleavage furrow-specific Vimentin 
phosphorylation as well as other proteins involved in cyto-
kinesis, such as Myosin II regulatory light chain and glial 
fibrillary astrocytic protein (GFAP) [19,20]. In the current 
study, loss of function of AURKB by RNAi caused im-
proper positioning of the cleavage furrows followed by un-
equal cell division in some of the early embryos; it would 
also compromise the spindle checkpoint because its activity 
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is required for checkpoint protein recruitment [19], which 
might provide a good explanation for why down-regulation 
of AURKB generated multinuclear phenotype and asym-
metric division. 
It is widely accepted that an extracellular signal regulated 
kinase (ERK) cascade acts at different steps during matura-
tion and regulates meiosis in oocytes of various species [21]. 
A recent study in sea urchin embryos also showed that a 
MEK/ERK-like cascade was transiently activated at the 
time of mitosis [22]. Mos was once thought to play a role in 
regulating mitotic metaphase arrest of early mammalian 
embryos; however, according to the study of Kashima et al. 
[23], the activation of MAPK and ribosomal protein S6 ki-
nase (Rsk) did not induce mitotic arrest in early mouse em-
bryos. We reported here that ERK1/2 was present and 
highly phosphorylated at G2/M phases during the first mi-
tosis of mouse zygotes, and showed that the ERK1/2 func-
tion was required for the proper development of mouse zy-
gotes. A study in somatic cells treated with MEK inhibitors 
reported mitotic defects, such as poorly defined mitotic axis 
and chromosome separation, suggesting that an ERK cas-
cade acts at different levels of mitotic spindle formation 
[24]. MEK inhibitors could induce spindle poles to split and 
then lead to the formation of tri- or tetrapolar spindles under 
these conditions. This could be why we frequently observed 
formation of two daughter cells of different sizes in zygotes 
treated with MEK inhibitors. In the study of sea urchin em-
bryos, ERK cascade was shown to be a part of a control 
mechanism that regulates mitotic spindle formation and the 
attachment of chromosomes to the spindle during the first 
mitosis [22]. Another example is that immunodepletion of 
MAPK in cycling Xenopus extracts or treatment with 
PD98059 caused termination of mitosis and mitotic micro-
tubules abnormality followed by an unequal segregation of 
sister chromatids [25]. Interestingly, in our study, protein 
expression patterns of total and activated ERK1/2 were both 
similar to that of AURKB: low at G1/S phases and peaking 
at M phase. In addition, the inactivation of ERK1/2 resulted 
in decreases of the AURKB protein levels and kinase activ-
ity. Irregular division was detected in the AURKB-knock- 
down group and the MAPK inactivation group. Similar to 
our findings, another study demonstrated that AURKA, 
along with other kinetochore-related proteins, was 
down-regulated by inactivation through the MAPK pathway 
in pancreatic cancer [26]. Another report concluded that 
c-Jun N-terminal kinase (JNK) signaling promoted entry 
into mitosis by regulating activation and expression of 
AURKB [27]. Together with our findings, these observa-
tions could imply some degree of crosstalk between 
AURKB and the MAPK signaling pathway. 
In conclusion, we report that Aurora kinase B is required 
for the early development of mouse zygotes; we also reveal 
a possibility of AURKB involvement in the MAPK pathway. 
Future studies should focus on further exploring the mecha-
nism and determining the targets of Aurora kinase B under-
lying the regulatory function in mammalian early embryon-
ic development. 
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